AstraZeneca Secures the EC Approval of Imfinzi as a Perioperative Therapy for G/GEJ Cancers

Why It Matters

Introducing immunotherapy into the curative‑intent setting could reshape standard of care for gastric cancers, offering patients a measurable survival advantage. The approval also signals growing confidence in checkpoint inhibitors for earlier disease stages, expanding market opportunities for AstraZeneca.

Key Takeaways

• EC approves Imfinzi+FLOT for resectable gastric cancers
• Phase III MATTERHORN shows 29% EFS improvement
• 3‑year overall survival rises to 69% versus 62%
• Benefit observed irrespective of PD‑L1 expression
• Japan regulatory review now underway

Pulse Analysis

The European Commission’s endorsement of Imfinzi plus FLOT marks a pivotal shift in the therapeutic landscape for gastric and gastro‑esophageal junction cancers. Historically, perioperative treatment has relied on chemotherapy alone, with limited options to improve long‑term outcomes. By integrating a PD‑L1 checkpoint inhibitor into the pre‑ and post‑surgical regimen, AstraZeneca offers clinicians a new tool that aligns with evolving precision‑medicine strategies, potentially setting a new benchmark for curative‑intent care across the EU.

Data from the MATTERHORN Phase III trial underpin this regulatory milestone. Among 948 participants, the combination achieved a 29% relative gain in event‑free survival, with median EFS not yet reached versus 32.8 months for chemotherapy alone. The survival curves diverged early, delivering a 1‑year EFS of 78.2% compared with 74% and a 24‑month rate of 67.4% versus 58.5%. Overall survival analysis revealed a 22% reduction in death risk, translating to a three‑year survival advantage of 69% over 62%, independent of PD‑L1 expression—a notable finding that broadens the eligible patient pool.

From a commercial perspective, the approval opens a sizable European market for immuno‑oncology in early‑stage disease, complementing AstraZeneca’s existing oncology portfolio. Ongoing regulatory review in Japan could unlock additional revenue streams in Asia, while competitors may accelerate their own perioperative immunotherapy programs. The move also reinforces the industry trend of moving checkpoint inhibitors upstream in the treatment algorithm, prompting payers and providers to reassess cost‑effectiveness models and guideline recommendations. As real‑world data accumulate, Imfinzi’s perioperative role could become a reference standard, influencing future trial designs and combination strategies.